|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to evaluate the concordance of EGFR mutation detection between paired primary or recurrent samples, and cerebrospinal fluid (CSF) cytology samples of lung cancer patients.
|
30471155 |
2019 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Epidermal growth factor receptor (EGFR), a cancer-driven gene, plays an important role in tumorigenesis of lung cancer.
|
31182926 |
2019 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Here, we demonstrate that apigenin combined with gefitinib inhibits multiple oncogenic drivers such as c-Myc, HIF-1α, and EGFR, reduces Gluts and MCT1 protein expression, and inactivates the 5' adenosine monophosphate-activated protein kinase (AMPK) signaling, which regulates glucose uptake and maintains energy metabolism, leading to impaired energy utilization in EGFR L858R-T790M-mutated H1975 lung cancer cells.
|
30967777 |
2019 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
But drastic structural differences can be found between lung cancer and its normal control, including the gain of functional modules for cellular proliferations such as EGFR and PDGFRA, as well as the lost of the important IL6 module, supporting their roles as potential drug targets.
|
27542180 |
2019 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In this study, we evaluated the epidermal growth factor receptor (EGFR) mutation status of samples of lung cancer patients stored before introduction of the plasma EGFR test at our institution.
|
30888199 |
2019 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Specific mutations significantly affect response to epidermal growth factor tyrosine kinase inhibitor (EGFR-TKI) treatment in lung cancer patients.
|
31132309 |
2019 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
The analysis of p22<sup>phox</sup> in lung carcinoma tissues could provide new insights into the selection of chemotherapy for the patients with EGFR-TKI resistant LUAD.
|
30800222 |
2019 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Compared to the EGFR wild-type lung cancer, mutated EGFR harboured significantly increased mutant p53-positive or TTF-1-positive tumors (P<0.001 and<0.001, respectively).
|
31062864 |
2019 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The identification of activating mutations in the epidermal growth factor receptor (EGFR) gene (deletions in exon 19 [Del19] and point mutation L858R in exon 21) has been the first important step toward molecularly guided precision therapy in lung cancer.
|
31564835 |
2019 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Correction: Monitoring <i>EGFR</i>-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer.
|
31069018 |
2019 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In this study, we investigated the role of miR-206 in IL6-induced gefitinib-resistant EGFR-mutated lung cancer cell lines.
|
31507089 |
2019 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The targeting therapy of EGFR signaling pathway in non-small cell lung cancer (NSCLC) has achieved a certain effect, but the two mutation of EGFR and other mechanisms of lung cancer resistance still greatly reduce the therapeutic effect of chemotherapy on it.
|
31839821 |
2019 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
EGFR rs2233947 correlated with lung cancer in males, smokers, and in the squamous cell carcinoma lung cancer subtype (P<0.01).
|
31518089 |
2019 |
|
Carcinoma of lung
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Further, clinical analysis showed that STC2 expression was increased after the development of EGFR TKI resistance and that higher levels were correlated with shorter progression-free survival in EGFR TKI-treated lung cancer patients.
|
31162839 |
2019 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Functional analysis of the five genes and their protein-protein interaction partners indicated that they are functionally enriched in cell cycle, endocytosis, and EGFR regulation, which are biological processes associated with lung cancer and drug resistance.
|
31407494 |
2019 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The V370D mutation abrogated HGF-dependent drug resistance of lung cancer cells to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI).
|
31342590 |
2019 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has been frequently used in targeted therapy for lung cancer.
|
30628660 |
2019 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy.
|
30639621 |
2019 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The proposed methods are then applied to a study which aims to compare two molecular tests for detecting EGFR mutations in lung cancer patients.
|
28814156 |
2019 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Therefore, this paper describes a retrospective study which was conducted to understand the clinicopathologic characteristics and epidermal growth factor receptor (EGFR) mutations in these young lung cancer patients.
|
30522775 |
2019 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
To inhibit EGFR-mediated signals, multiple EGFR tyrosine kinase inhibitors (EGFR-TKI) have been developed; however, approximately one third of patients with <i>EGFR</i>-mutated lung cancer do not respond to EGFR-TKIs.
|
31253648 |
2019 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In mutant-EGFR-driven lung cancer, MuSyC reveals that combining a mutant-EGFR inhibitor with inhibitors of other kinases may result only in synergistic potency, whereas synergistic efficacy can be achieved by co-targeting mutant-EGFR and epigenetic regulation or microtubule polymerization.
|
30797775 |
2019 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Repeat percutaneous transthoracic needle aspirations and biopsies for postprogression molecular profiling of epidermal growth factor receptor (<i>EGFR</i>)-mutant lung cancer are safe in everday clinical practice.
|
31152082 |
2019 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
It is unknown whether tyrosine kinase inhibitors targeting epidermal growth factor receptor (EGFR) can be discontinued in patients in whom <i>EGFR</i>-mutated lung cancer has well stabilised.
|
30709831 |
2019 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Distribution of EGFR SNPs -191C/A and 181946G/A in patients with lung cancer depending on smoking status in the Republic of Srpska, Bosnia and Herzegovina.
|
29745081 |
2019 |